

Review Article

The constitutive activity of the viral-encoded G protein-coupled receptor US28 supports a complex signalling network contributing to cancer development

Carole A. Daly¹, Martine J. Smit² and  Bianca Plouffe¹

¹Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, U.K.; ²Amsterdam Institute for Molecular and Life Sciences, VU University Amsterdam, Amsterdam, The Netherlands

Correspondence: Bianca Plouffe (b.plouffe@qub.ac.uk)



US28 is a viral G protein-coupled receptor (GPCR) encoded by the human cytomegalovirus (HCMV). This receptor, expressed both during lytic replication and viral latency, is required for latency. US28 is binding to a wide variety of chemokines but also exhibits a particularly high constitutive activity robustly modulating a wide network of cellular pathways altering the host cell environment to benefit HCMV infection. Several studies suggest that US28-mediated signalling may contribute to cancer progression. In this review, we discuss the unique structural characteristics that US28 acquired through evolution that confer a robust constitutive activity to this viral receptor. We also describe the wide downstream signalling network activated by this constitutive activation of US28 and discuss how these signalling pathways may promote and support important cellular aspects of cancer.

Introduction

G protein-coupled receptors (GPCRs) represent the largest transmembrane receptor family, including ~800 members and are target of over 30% of all therapeutic drugs [1] due to their substantial involvement in physiological processes. GPCRs modulate these processes by regulating intracellular signalling cascades in response to neurotransmitters, photons, ions, odorants and hormones. Agonist binding to these receptors at the plasma membrane stabilise an active GPCR conformation detected by heterotrimeric G proteins composed of an α , β and γ subunit [2]. This leads to the exchange of GDP for GTP from the $G\alpha$ subunit triggering its dissociation from the $G\beta\gamma$ dimer. Both the $G\alpha$ and the $G\beta\gamma$ subunits can modulate various cell signalling pathways by activating downstream effectors [3].

There are four families of heterotrimeric $G\alpha$ proteins, based on the sequence and functional similarities. The $G\alpha_s/olf$ family is composed of two members: $G\alpha_s$ and $G\alpha_{olf}$, both activating their effector adenylyl cyclase (AC), responsible for the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The $G\alpha_i/o$ family is composed of six members ($G\alpha_i1$, $G\alpha_i2$, $G\alpha_i3$, $G\alpha_oA$, $G\alpha_oB$ and $G\alpha_z$) inhibiting AC and consequently cAMP production. The third family ($G\alpha_q/11$) is composed of four members: $G\alpha_q$, $G\alpha_{11}$, $G\alpha_{14}$ and $G\alpha_{16}$. These $G\alpha$ proteins activate phospholipase C β (PLC β), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP₂) into diacylglycerol (DAG) and inositol trisphosphate (IP₃). DAG activates protein kinase C (PKC) and IP₃ opens the calcium channel IP₃ receptor on the endoplasmic reticulum (ER) membrane to release calcium from the ER into the cytosol. The increased concentration of cytosolic calcium by IP₃ leads to activation of calcium-dependent proteins, such as PKC and calmodulin. Members from the $G\alpha_q/11$ family are also reported to activate the Ras homolog family member A (RhoA), leading to activation

Received: 4 May 2020
 Revised: 5 July 2020
 Accepted: 14 July 2020

Version of Record published:
 11 August 2020

of the Rho-associated protein kinase (ROCK) involved in the actin cytoskeletal reorganisation [4,5]. The last $G\alpha$ protein family ($G\alpha_{12/13}$) is composed of two isoforms: $G\alpha_{12}$ and $G\alpha_{13}$. These $G\alpha$ proteins generally activate the Rho/ROCK pathway. $G\beta\gamma$ can also modulate the activity of downstream effectors such as AC, PLC β , voltage-gated calcium channels and inwardly rectifying potassium channels [6]. Although, due to the relatively higher amounts of $G\alpha$ proteins from the $G\alpha_i/o$ family, activation of these $G\alpha$ proteins is thought to be the primary source of $G\beta\gamma$ -mediated signalling.

G protein dissociation and signalling is followed by the recruitment of kinases, such as the G protein-coupled receptor kinases (GRKs) to the receptor [7] and phosphorylation of the GPCR at specific serine or threonine residues in the intracellular loops and C-terminal tail (CT), producing a distinct pattern of phosphorylation, or 'barcode' [8]. A protein called β -arrestin is then recruited to the phosphorylated receptor resulting in GPCR uncoupling from G proteins but also recruits adaptor proteins required for receptor internalisation via clathrin-coated pits, promoting GPCR internalisation into early endosomes. The 'barcode' dictates the fate of the receptor. While some GPCRs are targeted to lysosomes for degradation, others are recycled back to the plasma membrane. Alternatively, other receptors undergo persistent G protein activation in early endosomes, while others are transported to the Golgi to activate G proteins from this cellular compartment [9]. β -arrestin has been shown to be required for G protein signalling in intracellular compartments by forming a transient complex together with the receptor and G proteins, called 'megaplex' [10]. This megaplex has been hypothesised to occur for GPCRs having high affinity for β -arrestins.

Although the majority of GPCRs regulating human physiology are the product of a portion of the genome of an individual, a few GPCRs detected in a human body have a viral origin, acquired upon infection of the pathogen. One of these viruses is the human cytomegalovirus (HCMV), a member of the β -herpesviruses. Herpesviruses such as HCMV have evolved to encode viral GPCRs which are chemokine receptors believed to have been 'hijacked' from host genomes during evolution and severely modified and optimised for the virus's own benefit [11]. These viral GPCRs often exhibit particular characteristics such as high constitutive activity or promiscuous binding of ligands. The HCMV encodes four GPCR homologues: UL33, UL78, US27 and US28. UL33, UL78 and US27 are orphan viral GPCRs with no known ligands, but US28 binds with high affinity to many CC-type chemokines as well as CX3CL1 (fractalkine) [12]. US28 has 38% sequence homology with the human CX3CR1 receptor [13]. A recent study demonstrated that US28 can accommodate at least thousands of engineered chemokines [14]. This ability of US28 to bind to a high number of chemokines has been proposed as an evolutionary mechanism to serve as a chemokine sink to subvert and escape the host's immune system [15]. Indeed, the CT of US28 is rich in serine and threonine residues which, once phosphorylated by GRKs or other protein kinases, lead to rapid internalisation [16]. This robust internalisation of US28 results in 80% of the receptors located intracellularly as found for other HCMV-encoded GPCRs, but not all other viral GPCRs which are found at the plasma membrane [17,18]. As chemokines attract immunomodulatory cells, the ability of US28 to bind and sequester a large range of chemokines inside the host's cells by rapid internalisation is beneficial for immune evasion [19].

The molecular determinants of the constitutive activation of G proteins by US28

Despite the extraordinary ability to bind with high affinity to an impressive number of chemokines, US28 can also activate G proteins in absence of agonist through its robust constitutive activity. US28 has been reported to activate in a constitutive manner three families of $G\alpha$ proteins: the $G\alpha_q/11$ [17,20–31], $G\alpha_{12/13}$ [28,32] and $G\alpha_i/o$ [31] families in several cell types. Ligand-induced US28 signalling has been also reported, and is associated to many important functional consequences of HCMV [14,20,32–37]. In studies related to US28 constitutive activity, the $G\alpha_q$ G protein isoform is the most studied. The high constitutive activation of $G\alpha_q$ by US28 leads to a potent activation of PLC β [20,22,30,34,38]. It has been shown that inhibition of HCMV viral replication by the viral polymerase inhibitor phosphonoacetic acid (PAA) in HCMV-infected glioblastoma U373MG cells does not succeed to abrogate PLC β activation, despite the fact that US28 protein expression was undetectable by western blot [20]. Although activation of the pathways downstream of PLC β were not monitored, these results highlight the robust ability of US28 to activate $G\alpha_q$ in a constitutively active manner.

Recent crystal structures of US28 in complex with the human CX3CL1 reveal that US28 has evolved a highly stable active state [39]. Many structural features of US28 explain this constitutive activity. The conformation of the transmembrane (TM) 6 (TM6) in US28 is typical of an active-state GPCR [40]. Similarly to many

active-state GPCRs, US28 exhibits a large outward movement at the intracellular end of TM6 [39] (Figure 1). This open position of TM6 is partly due to the absence of a conserved acidic residue at position 6.30 normally forming a salt bridge with the positively charged and conserved arginine residue at position 3.50 within the DRY motif [40,41] (Figure 1). The absence of such salt bridge, known as ‘ionic lock’, prevents stabilisation of an inactive GPCR conformation. Another structural particularity of US28 contributing to its high constitutive activity is the presence of a hydrogen bond network connecting TM3, TM5 and TM7 present in previously solved active-state GPCR structures [40,42] (Figure 1). There is an inward position of TM7 caused by the formation of hydrogen bonds between tyrosine at position 7.53 with tyrosine 5.58 and isoleucine 3.43 through a water molecule [39] (Figure 1). The tyrosine 5.58, in turn, forms a hydrogen bond with the arginine at position 3.50 of the DRY motif (Figure 1). Finally, the structural environment around the aspartate at position 3.49, near the cytoplasmic end of TM3, also represents an adaptive evolutionary mechanism of US28 to promote a high constitutive activity. The arginine 139 in the second intracellular loop (ICL2) of US28 forms an ionic interaction with a unique glutamate at position 3.45 of US28 instead of contacting aspartate 3.49 [39]




Figure 1. The main structural determinants responsible for the high constitutive activity of US28.

The large outward position of TM6 due to the absence of ionic lock between residues 3.50 and 6.30 maintains US28 in an active conformation. The hydrogen bond network between TM3, TM5, and TM7 involving Y^{7.53}, Y^{5.58}, I^{3.43} and R^{3.50} induces an inward position of TM7. This inward position of TM7 is common in active GPCR structures. The ionic interaction between R139 in ICL2 and E^{3.45} instead of D^{3.49} destabilises the inactive state of US28. The shorter ICL2 preventing α -helix formation in this region also contributes to the absence of interaction between R139 and D^{3.49}.

(Figure 1). This interaction potentially destabilises the inactive state of US28. ICL2 of US28 is also shorter by four residues in US28 compared with most class A GPCRs (Figure 1). This shorter ICL2 is believed to prevent the formation of an α -helix [39]. As this α -helix is known to help to position the arginine of ICL2 in a way to interact with the aspartate 3.49, the lack of ICL2 secondary structure may provide the required flexibility for the arginine in ICL2 to adopt different structural states.

Although the DRY motif is not forming an ‘ionic lock’ with an acidic residue in TM6, it interacts with $G\alpha$ proteins and is consequently responsible for the observed constitutive activity of US28. Changes within the DRY motif by a point mutation in the arginine residue 3.50 (US28-R129A) disrupts and uncouples G protein binding to the receptor and markedly attenuates signalling [43]. As this G protein-uncoupled receptor is nonetheless expressed at similar levels than wild-type US28 [43,44], it was used in many studies [20,24,26,27,38] to demonstrate the importance of US28-mediated constitutive activation of G proteins in engaging several signalling pathways promoting cancer development.

The constitutive activity of US28 as a factor promoting cancer development

Although debated, HCMV infection has been reported to have important oncomodulatory properties on numerous cancers, such as breast [45], colorectal [46–48] and prostate [49] cancers, as well as Epstein Barr virus (EBV)-negative Hodgkin lymphoma [50], alveolar soft part sarcoma [51] and gliomas [29,52–56]. Although other proteins expressed by HCMV may play a role in the oncomodulatory properties of this virus, US28-mediated constitutive G protein signalling has been associated with acceleration of cell proliferation, angiogenesis, inflammation and metabolic remodelling (Figure 2), which are important components of cancer development [57].

Proliferation

HCMV infection modulates the host cell cycle to create an environment that is optimal for viral gene expression, DNA replication and production of infectious virus [58]. As an example, initiation of HCMV gene expression has been shown to require that the cells halt temporarily in G0 or G1 at the time of infection as infection of cells in the S phase blocked immediate early gene expression [59,60]. Modulation of the cell cycle machinery is also a hallmark of cancer and sustained cell proliferation is an important part of cancer development and progression [61]. Activation of the signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor, accelerates cellular proliferation by up-regulation of proteins involved in the control of cell cycle progression, such as cyclin D1 [62]. US28-mediated constitutive G protein activation was reported to increase the expression of cyclin D1 in mouse fibroblast NIH-3T3 cells stably transfected with US28 [24]. However, it would have been interesting to confirm these results in a human cell line. In agreement with its proliferative properties, dysregulation of STAT3 has been reported in 50–90% of all human cancers [63]. One of the receptors responsible for activation of STAT3 is the receptor of interleukin-6 (IL-6), a pleiotropic cytokine highly produced in the tumour-bearing host [64]. HCMV infection has been shown to induce IL-6 secretion by infected trophoblasts extracted from term and first trimester human placentas as well as infected choriocarcinoma JEG-3 cells [65]. Targeting IL-6 signalling has also been shown to suppress survival of glioma stem cells isolated from human glioblastoma xenografts (D456MG, D54MG) or from fresh human surgical specimens and tumour growth [66]. Notably, primary glioblastoma tumours contain both US28 and activated STAT3 [27,67]. In NIH-3T3 cells stably expressing US28, HEK-293T transiently transfected with US28, and in HCMV-infected malignant glioblastoma U373MG cells, the constitutive activation of $G\alpha_q$ by US28 is reported to enhance cell proliferation and DNA synthesis by activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) leading to secretion of IL-6 inducing STAT3 phosphorylation via Janus kinase 1 (JAK1) [27] (Figure 2). As it has been reported that IL-6 itself is transcriptionally activated by STAT3 [68], it may lead to an IL-6-STAT3 positive feedforward loop. Recently, a novel STAT3 inhibitor, napabucasin, was shown to suppress proliferation of U87MG and LN229 glioblastoma cells [69] highlighting the important role of STAT3 activation in proliferation of these cells. Another transcription factor known to activate the transcription of cyclin D1 is β -catenin. Chronic activation of β -catenin signalling is found in a variety of human malignancies, such as melanoma, colorectal and hepatocellular carcinomas [70]. Moreover, transgenic mice expressing US28 in intestinal epithelial cells has been shown to develop adenomas and adenocarcinomas that express abnormally high levels of nuclear β -catenin protein [71]. In line with these observations, it was reported




Figure 2. Cellular signalling pathways mediated by the constitutive activation of US28.

The constitutive activation of the heterotrimeric $G\alpha$ proteins from the $G\alpha_q/11$, $G\alpha_{12/13}$ and $G\alpha_{i/o}$ families as well as the constitutive recruitment of β -arrestin (in green circles) contribute to cell proliferation, angiogenesis, inflammation, and aerobic glycolysis, which are important cellular functions promoting cancer development. Each signalling pathway leading to a cell function is interconnected with the pathways controlling other functions by key multifunctional proteins. Transcription factors are depicted by yellow boxes.

that in human foreskin fibroblasts and human glioblastoma U373MG cells infected with HCMV, the constitutive activation of $G\alpha_q$ and G proteins from the $G\alpha_{12/13}$ family by US28 induces activation of β -catenin in a PLC β -independent manner via activation of Rho and ROCK [28] (Figure 2).

Angiogenesis and inflammation

Inflammation of host cells is a mechanism used by HCMV to increase its potential of replication. The inflammatory cytokine IL-6 has been reported to promote HCMV reactivation from latency in dendritic cells via p42/44 mitogen-activated protein kinases (MAPKs)-mediated transcriptional induction of major immediate early genes [72,73]. This has been shown to result in efficient progression of the virus life cycle and, ultimately, higher titres of infectious virus. Inflammation induced by HCMV infection may contribute to angiogenesis. HCMV infection of endothelial cells induces the expression of adhesion molecules, which enhance transendothelial cell migration of inflammatory cells including monocytes [74]. Infected monocytes are also known to disseminate HCMV throughout the body, including the vasculature [75]. The infected monocytes enter the vasculature, where they mature, initiate the viral infection programme and stimulate virus replication. Angiogenesis and inflammation are two important physiological processes promoting and supporting cancer development.

To grow, all solid tissues require a proper vasculature that provides oxygen, nutrients and waste disposal. Consequently, early activation of angiogenic processes is required to sustain proliferation of tumour cells, but also metastasis [76]. Early during tumour progression, hypoxia triggers the transcription of several genes, such as the hypoxia inducible factor-1 (HIF-1). This transcription factor contains an oxygen-regulated α subunit and a stable β subunit, which upon complex formation activates transcription of many genes involved in proliferation, angiogenesis and glycolysis [77]. HIF-1 α is degraded rapidly within cells under normoxic conditions preventing dimerisation with HIF-1 β to become an active transcription factor. In cancer cells, expression of oxygen-regulated subunit α is increased by either HIF-1 α protein synthesis and stability or by increase in mRNA levels in normoxic conditions [77]. This occurs through mutations of regulatory proteins, but also by infection with oncogenic viruses, such as HCMV, as demonstrated in human foetal foreskin fibroblasts HFFF2 infected with HCMV (AD169 strain) 24 h post-infection [78]. HIF-1 promotes transcription of the vascular endothelial growth factor (VEGF), a key player in tumour angiogenesis [79]. US28-expressing NIH-3T3 fibroblasts and U251 glioma cells have been shown to promote the transcriptional activity of HIF-1 α under normoxic conditions via constitutive activation of G_{α_q} by stimulating the calcium/calmodulin-dependent protein kinase type II (CaMKII) and the subsequent stimulation of Akt [29] (Figure 2). NF- κ B constitutively activated by US28 also converges toward VEGF secretion by several pathways. One of them is by increased expression of cyclooxygenase-2 (COX-2), a key mediator of inflammation by its production of prostaglandin E2 (PGE2) [80] and a major determinant in several forms of cancer, as demonstrated in NIH-3T3 stably expressing US28 and in HCMV-infected human foreskin fibroblast BJ cells [26] (Figure 2). Hence, treatment with Celecoxib, a COX-2 selective inhibitor, has been shown to significantly reduce tumour formation in a murine model of mice injected with US28-transfected NIH-3T3 cells by repressing the US28-induced angiogenic activity. STAT3 activation by US28-mediated IL-6 secretion was also reported to be involved in VEGF production in NIH-3T3 cells stably transfected with US28 and U373MG cells 48 h after infection with HCMV as well as in primary glioblastoma specimens from patient samples [27] (Figure 2). Both p38- and p42/44-MAPKs were also reported to be involved in VEGF production by the constitutive activation of NF- κ B by US28 in COS-7 cells transiently transfected with US28 [24] (Figure 2). This would need to be confirmed in the context of a HCMV infection. As the IL-6 receptor is reported to activate both p38- and p42/44-MAPK pathways [81,82], this MAPK-mediated VEGF secretion may come from the NF- κ B-induced IL-6 secretion activated by US28. Additionally, although this has been shown in a heterologous expression system, the constitutive recruitment of β -arrestin seems to be required for a maximal activation of the p38-MAPK pathway [16], suggesting a partial role of β -arrestin in US28-mediated p38-MAPK activation (Figure 2). US28-mediated activation of MAPKs and of PLC β was also shown to mediate activation of the cAMP response element binding protein (CREB) in HEK-293 cells and COS-7 cells transiently transfected with US28 [31,38], a transcription factor linked to a broad range of cellular processes, such as cell proliferation, differentiation, survival, angiogenesis, immune response, migration and invasion [83] (Figure 2). Although this has not been proven in the context of HCMV infection, in HEK-293 cells transiently transfected with US28, this activation of CREB by US28 has also been reported to stimulate the major immediate early gene promoter/enhancer (MIE) [84], thus playing a key role in the activation and replication of HCMV, but also in HCMV reactivation from latency [85].

Nuclear factor of activated T cells (NFAT) are transcription factors playing a crucial role in vascular development and are linked to transcription of VEGF [86]. Many studies also report the role of NFAT as a transcription factor that up-regulates the expression of COX-2 [87–91]. Accumulating studies have suggested that NFAT is involved in many aspects of cancer, including carcinogenesis, metastasis, cancer cell proliferation and tumour microenvironment [92]. The NFAT family is composed of five members, known as NFAT1–NFAT5. While NFAT5 is regulated by osmotic stress, NFAT1–NFAT4 proteins are activated by increased cytosolic calcium concentration [92]. Dephosphorylation of the NFAT regulatory domain results in the nuclear translocation and activation of NFAT. Different proteins constitutively activated by US28 have been shown to be involved in NFAT activation, such as PLC β , P38- and p42/44-MAPKs, and Gi/o proteins in HEK293 cells transiently transfected with US28 [31] (Figure 2). The involvement of the constitutive activation of $G_{\alpha i/o}$ proteins has been hypothesised to be mediated through $G_{\beta\gamma}$ (Figure 2). A subsequent study using the same cellular model has shown that US28 constitutively interacts with the sarco/endoplasmic reticulum calcium ATPase 2 (SERCA2) and inhibits its ATPase activity [93]. This finding would need to be confirmed in a cellular model more physiologically relevant in the context of cancer. SERCA2 transport calcium from the cytosol to the reticulum lumen against gradient via ATP hydrolysis, leading to a reduction of calcium concentration in the cytosol. US28, by constitutively inhibiting SERCA2 ATPase activity, was shown to increase cytosolic calcium concentration which

favour NFAT activation and the associated increased expression of COX-2 in human umbilical vein endothelial cells (HUVECs) [93] (Figure 2). Furthermore, treatment of xenograft mice bearing sinus venosus endothelial cells (SVECs) expressing US28 with cyclosporine A, an inhibitor of calcineurin, a protein phosphatase known to dephosphorylate and consequently activate NFAT [94], was shown to reduce the induced tumour volume by 50% [93].

Metabolic reprogramming and glycolysis

Metabolic reprogramming in host cells facilitates optimal virus production as it relies on the metabolic network of the host cell to provide energy and macromolecular precursors to fuel viral replication. In line with this affirmation, HCMV infection has been shown to enhance glucose uptake [95] and glucose withdrawal during HCMV infection to reduce virus replication [96,97]. Reprogramming of energy metabolism conferred by virus infection often mirror metabolic changes seen in cancer cells, such as up-regulation of nutrient consumption and anabolism to support rapid cell growth. Therefore, by promoting its viral replication, HCMV-mediated metabolic reprogramming also supports the high metabolic demands of cancer cells.

Transformed cells switch from the slow yet energetically favourable oxidative phosphorylation towards the fast and less glucose-efficient aerobic glycolysis [98]. Pyruvate kinase M2 (PKM2) is an important glycolytic enzyme in energy metabolism with a distinct dual role depending on its oligomeric state. Tetrameric PKM2 drives the cycle of oxidative phosphorylation [99], while the PKM2 dimer is associated with increased glycolytic flux and lactate secretion [100]. In addition, dimeric PKM2 is able to translocate to the nucleus where it functions as a co-transcription factor regulating expression of proliferative genes thereby promoting tumorigenesis [99,101,102]. PKM2 phosphorylation at tyrosine 105 has been shown to inhibit formation of the tetramer and to promote the PKM2 dimer [100,103]. PKM2 stimulates both HIF-1 activity and transcription [101,104]. Conversely, the transcription of PKM2 is under the control of HIF-1, creating a feedforward loop, enhancing activity of both key metabolic proteins [105]. In both US28-expressing NIH-3T3 fibroblasts and U251 glioma cells, an increased phosphorylation of tyrosine 105 of PKM2 and a corresponding increase of PKM2 dimer compared with mock cells was observed, and this effect was mediated by HIF-1 [29] (Figure 2). These results suggest that US28 induces metabolic reprogramming by inducing a switch from oxidative phosphorylation to aerobic glycolysis. Furthermore, it was also shown that the activation of HIF-1 enhanced by PKM2 dimer and G α q-dependent Akt activation by US28 also increases mRNA levels of the glucose transporter type 1 (GLUT1) and metabolic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [29] (Figure 2). GLUT1 facilitates entry of glucose into cells and consequently helps to support the high rate of glucose consumption characteristic of cancer cells [106]. The catalytic function of GAPDH is one of the critical rate-limiting steps of glycolysis [107] and computational modelling and metabolomics show that aerobic glycolysis in cancer flux through GAPDH [108]. Consequently, both GLUT1 and GAPDH help to support the PKM2 dimer-mediated aerobic glycolysis.

Conclusion

Altogether, these studies highlight the fact that the robust constitutive activity of US28 underlies a complex network of signalling pathways which may contribute to cancer development by activating four important functional axes: cell proliferation, angiogenesis, inflammation and aerobic glycolysis. Furthermore, each axis seems to be interconnected with others via involvement of multifunctional proteins able to create some 'branching' through their respective signalling networks. These interconnection points probably contribute to the oncomodulatory role of US28 by preserving activity of all the four axes if for a given reason a protein is not functional or present in a certain cellular context. Evolution has shaped US28 to be 'fully equipped' with several molecular tricks to modify its host to support its infection and proliferation.

Perspectives

- **Importance of the field:** Understanding the molecular mechanisms underlying the constitutive signalling of US28 represents a promising avenue to develop new therapeutic solutions to fight against cancer. As US28 is also expressed and potently signals during the latent viral phase, the impact of investigating US28-mediated signalling can also have great impact on CMV-positive and immunocompetent population.

- **Current thinking:** Overall, there is growing evidence that US28-mediated signalling may represent one of the multifactorial aspects underlying cancer development. By tricking the host cell, this receptor initiates a multitude of signalling pathways favouring HCMV propagation and replication by activating cellular functions linked to cancer development.
- **Future direction:** Antivirals target the lytic phase and not the latent phase of the viral life cycle. As studies show that limited and almost undetectable expression of US28 during the latent phase is sufficient to robustly signal, blocking the constitutive activity of US28 by inverse agonists may be effective. Such an approach has to be actively investigated as those modulators may inhibit the US28-mediated signalling pathways that potentially contribute to cancer in HCMV-positive patients.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

C.A.D. is supported by a PhD scholarship from the Department for Education (DfE) from Queen's University Belfast. M.J.S. is supported by the Dutch Research Council (NWO—Vici 016.140.657). B.P. is funded by a Patrick G. Johnston/Vice-Chancellor's Fellowship from Queen's University Belfast and a Wellcome Trust Seed Award in Science (215229/Z/19/Z).

Author Contribution

All authors contributed to the writing and approved the final version of the manuscript.

Abbreviations

AC, adenylyl cyclase; AP-2, activator protein-2; ATP, adenosine triphosphate; CaMKII, calcium/calmodulin-dependent protein kinase type II; cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase-2; CREB, cyclic AMP response element binding protein; CT, C-terminal tail; DAG, diacylglycerol; EBV, Epstein Barr virus; ER, endoplasmic reticulum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GBM, glioblastoma multiforme; GLUT1, glucose transporter type 1; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; HCMV, human cytomegalovirus; HEK, human embryonic kidney; HIF-1 α , hypoxia inducible factor 1 α ; HUVECs, human umbilical vein endothelial cells; ICL, intracellular loop; IL-6, interleukin-6; IP₃, inositol trisphosphate; MAPK, mitogen-activated protein kinase; MIE, major immediate early gene promoter/enhancer; NFAT, nuclear factor of activated T cells; NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells; PAA, phosphonoacetic acid; PGE₂, prostaglandin E₂; PIP₂, phosphatidylinositol-4,5-bisphosphate; PKC, protein kinase C; PKM2, pyruvate kinase M2; PLC β , phospholipase C β ; RhoA, Ras homolog family member A; ROCK, Rho-associated protein kinase; SERCA2, sarco/endoplasmic reticulum calcium ATPase 2; STAT3, signal transducer and activator of transcription 3; SVECs, sinus venous endothelial cells; TM, transmembrane; VEGF, vascular endothelial growth factor.

References

- 1 Hauser, A.S., Attwood, M.M., Rask-Andersen, M., Schiöth, H.B. and Gloriam, D.E. (2017) Trends in GPCR drug discovery: new agents, targets and indications. *Nat. Rev. Drug Discov.* **16**, 829–842 <https://doi.org/10.1038/nrd.2017.178>
- 2 Hilger, D., Masureel, M. and Kobilka, B.K. (2018) Structure and dynamics of GPCR signaling complexes. *Nat. Struct. Mol. Biol.* **25**, 4–12 <https://doi.org/10.1038/s41594-017-0011-7>
- 3 Syrovatkin, V., Alegre, K.O., Dey, R. and Huang, X.Y. (2016) Regulation, signaling, and physiological functions of G-proteins. *J. Mol. Biol.* **428**, 3850–3868 <https://doi.org/10.1016/j.jmb.2016.08.002>
- 4 Lowry, W.E., Huang, J., Ma, Y.C., Ali, S., Wang, D., Williams, D.M. et al. (2002) Csk, a critical link of g protein signals to actin cytoskeletal reorganization. *Dev. Cell* **2**, 733–744 [https://doi.org/10.1016/S1534-5807\(02\)00175-2](https://doi.org/10.1016/S1534-5807(02)00175-2)
- 5 Lutz, S., Freichel-Blomquist, A., Yang, Y., Rumenapp, U., Jakobs, K.H., Schmidt, M. et al. (2005) The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. *J. Biol. Chem.* **280**, 11134–9 <https://doi.org/10.1074/jbc.M411322200>

- 6 Khan, S.M., Sleno, R., Gora, S., Zylbergold, P., Laverdure, J.P., Labbe, J.C. et al. (2013) The expanding roles of Gbetagamma subunits in G protein-coupled receptor signaling and drug action. *Pharmacol. Rev.* **65**, 545–577 <https://doi.org/10.1124/pr.111.005603>
- 7 Gurevich, V.V. and Gurevich, E.V. (2019) GPCR signaling regulation: the role of GRs and arrestins. *Front. Pharmacol.* **10**, 125 <https://doi.org/10.3389/fphar.2019.00125>
- 8 Bahouth, S.W. and Nooh, M.M. (2017) Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks. *Cell Signal.* **36**, 42–55 <https://doi.org/10.1016/j.cellsig.2017.04.015>
- 9 Lobingier, B.T. and von Zastrow, M. (2019) When trafficking and signaling mix: How subcellular location shapes G protein-coupled receptor activation of heterotrimeric G proteins. *Traffic* **20**, 130–136 <https://doi.org/10.1111/tra.12634>
- 10 Thomsen, A.R.B., Plouffe, B., Cahill, III, T.J., Shukla, A.K., Tarrasch, J.T., Dosey, A.M. et al. (2016) GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling. *Cell* **166**, 907–919 <https://doi.org/10.1016/j.cell.2016.07.004>
- 11 Slinger, E., Langemeijer, E., Siderius, M., Vischer, H.F. and Smit, M.J. (2011) Herpesvirus-encoded GPCRs rewire cellular signaling. *Mol. Cell. Endocrinol.* **331**, 179–184 <https://doi.org/10.1016/j.mce.2010.04.007>
- 12 Frank, T., Niemann, I., Reichel, A. and Stamminger, T. (2019) Emerging roles of cytomegalovirus-encoded G protein-coupled receptors during lytic and latent infection. *Med. Microbiol. Immunol.* **208**, 447–456 <https://doi.org/10.1007/s00430-019-00595-9>
- 13 Chee, M.S., Satchwell, S.C., Preddie, E., Weston, K.M. and Barrell, B.G. (1990) Human cytomegalovirus encodes three G protein-coupled receptor homologues. *Nature* **344**, 774–777 <https://doi.org/10.1038/344774a0>
- 14 Miles, T.F., Spiess, K., Jude, K.M., Tsutsumi, N., Burg, J.S., Ingram, J.R. et al. (2018) Viral GPCR US28 can signal in response to chemokine agonists of nearly unlimited structural degeneracy. *eLife* **7**, e35850 <https://doi.org/10.7554/eLife.35850>
- 15 Randolph-Habecker, J.R., Rahill, B., Torok-Storb, B., Vieira, J., Kolattukudy, P.E., Rovin, B.H. et al. (2002) The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. *Cytokine* **19**, 37–46 <https://doi.org/10.1006/cyto.2002.0874>
- 16 Miller, W.E., Houtz, D.A., Nelson, C.D., Kolattukudy, P.E. and Lefkowitz, R.J. (2003) G-protein-coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR. *J. Biol. Chem.* **278**, 21663–21671 <https://doi.org/10.1074/jbc.M303219200>
- 17 Fraile-Ramos, A., Kledal, T.N., Pelchen-Matthews, A., Bowers, K., Schwartz, T.W. and Marsh, M. (2001) The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. *Mol. Biol. Cell* **12**, 1737–1749 <https://doi.org/10.1091/mbc.12.6.1737>
- 18 Vischer, H.F., Siderius, M., Leurs, R. and Smit, M.J. (2014) Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? *Nat. Rev. Drug Discov.* **13**, 123–139 <https://doi.org/10.1038/nrd4189>
- 19 Bodaghi, B., Jones, T.R., Zipeto, D., Vita, C., Sun, L., Laurent, L. et al. (1998) Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. *J. Exp. Med.* **188**, 855–866 <https://doi.org/10.1084/jem.188.5.855>
- 20 Miller, W.E., Zagorski, W.A., Breneman, J.D., Avery, D., Miller, J.L. and O'Connor, C.M. (2012) US28 is a potent activator of phospholipase C during HCMV infection of clinically relevant target cells. *PLoS One* **7**, e50524 <https://doi.org/10.1371/journal.pone.0050524>
- 21 Casarosa, P., Bakker, R.A., Verzijl, D., Navis, M., Timmerman, H., Leurs, R. et al. (2001) Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. *J. Biol. Chem.* **276**, 1133–1137 <https://doi.org/10.1074/jbc.M008965200>
- 22 Minisini, R., Tulone, C., Luske, A., Michel, D., Mertens, T., Gierschik, P. et al. (2003) Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28. *J. Virol.* **77**, 4489–4501 <https://doi.org/10.1128/JVI.77.8.4489-4501.2003>
- 23 Bakker, R.A., Casarosa, P., Timmerman, H., Smit, M.J. and Leurs, R. (2004) Constitutively active Gq/11-coupled receptors enable signaling by co-expressed G(i/o)-coupled receptors. *J. Biol. Chem.* **279**, 5152–5161 <https://doi.org/10.1074/jbc.M309200200>
- 24 Maussang, D., Verzijl, D., van Walsum, M., Leurs, R., Holl, J., Pleskoff, O. et al. (2006) Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 13068–13073 <https://doi.org/10.1073/pnas.0604433103>
- 25 Moepf, B., Tulone, C., Kern, C., Minisini, R., Michels, G., Vatter, P. et al. (2008) Constitutive serum response factor activation by the viral chemokine receptor homologue pUS28 is differentially regulated by Galpha(q/11) and Galpha(16). *Cell Signal.* **20**, 1528–1537 <https://doi.org/10.1016/j.cellsig.2008.04.010>
- 26 Maussang, D., Langemeijer, E., Fitzsimons, C.P., Stigter-van Walsum, M., Dijkman, R., Borg, M.K. et al. (2009) The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. *Cancer Res.* **69**, 2861–2869 <https://doi.org/10.1158/0008-5472.CAN-08-2487>
- 27 Slinger, E., Maussang, D., Schreiber, A., Siderius, M., Rahbar, A., Fraile-Ramos, A. et al. (2010) HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. *Sci. Signal.* **3**, ra58 <https://doi.org/10.1126/scisignal.2001180>
- 28 Langemeijer, E.V., Slinger, E., de Munnik, S., Schreiber, A., Maussang, D., Vischer, H. et al. (2012) Constitutive beta-catenin signaling by the viral chemokine receptor US28. *PLoS One* **7**, e48935 <https://doi.org/10.1371/journal.pone.0048935>
- 29 de Wit, R.H., Mujic-Delic, A., van Senten, J.R., Fraile-Ramos, A., Siderius, M. and Smit, M.J. (2016) Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1alpha/PKM2 axis in glioblastoma cells. *Oncotarget* **7**, 67966–67985 <https://doi.org/10.18632/oncotarget.11817>
- 30 Wu, S.E. and Miller, W.E. (2016) The HCMV US28 vGPCR induces potent Galphaq/PLC-beta signaling in monocytes leading to increased adhesion to endothelial cells. *Virology* **497**, 233–243 <https://doi.org/10.1016/j.virol.2016.07.025>
- 31 McLean, K.A., Holst, P.J., Martini, L., Schwartz, T.W. and Rosenkilde, M.M. (2004) Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. *Virology* **325**, 241–251 <https://doi.org/10.1016/j.virol.2004.04.027>
- 32 Melnychuk, R.M., Streblov, D.N., Smith, P.P., Hirsch, A.J., Pancheva, D. and Nelson, J.A. (2004) Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through Galpha12. *J. Virol.* **78**, 8382–8391 <https://doi.org/10.1128/JVI.78.15.8382-8391.2004>
- 33 Crawford, L.B., Caposio, P., Kreklywich, C., Pham, A.H., Hancock, M.H., Jones, T.A. et al. (2019) Human cytomegalovirus US28 ligand binding activity is required for latency in CD34(+) hematopoietic progenitor cells and humanized NSG mice. *mBio* **10**, e01889–19 <https://doi.org/10.1128/mBio.01889-19>

- 34 Stropes, M.P., Schneider, O.D., Zagorski, W.A., Miller, J.L. and Miller, W.E. (2009) The carboxy-terminal tail of human cytomegalovirus (HCMV) US28 regulates both chemokine-independent and chemokine-dependent signaling in HCMV-infected cells. *J. Virol.* **83**, 10016–10027 <https://doi.org/10.1128/JVI.00354-09>
- 35 Billstrom, M.A., Johnson, G.L., Avdi, N.J. and Worthen, G.S. (1998) Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. *J. Virol.* **72**, 5535–5544 <https://doi.org/10.1128/JVI.72.7.5535-5544.1998>
- 36 Hjort, G.M., Kilerich-Pedersen, K., Selmecki, D., Kledal, T.N. and Larsen, N.B. (2013) Human cytomegalovirus chemokine receptor US28 induces migration of cells on a CX3CL1-presenting surface. *J. Gen. Virol.* **94**(Pt 5), 1111–1120 <https://doi.org/10.1099/vir.0.047290-0>
- 37 Streblov, D.N., Vomaske, J., Smith, P., Melnychuk, R., Hall, L., Pancheva, D. et al. (2003) Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. *J. Biol. Chem.* **278**, 50456–50465 <https://doi.org/10.1074/jbc.M307936200>
- 38 Waldhoer, M., Kledal, T.N., Farrell, H. and Schwartz, T.W. (2002) Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities. *J. Virol.* **76**, 8161–8168 <https://doi.org/10.1128/JVI.76.16.8161-8168.2002>
- 39 Burg, J.S., Ingram, J.R., Venkatakrishnan, A.J., Jude, K.M., Dukkupati, A., Feinberg, E.N. et al. (2015) Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. *Science* **347**, 1113–1117 <https://doi.org/10.1126/science.aaa5026>
- 40 Venkatakrishnan, A.J., Deupi, X., Lebon, G., Tate, C.G., Schertler, G.F. and Babu, M.M. (2013) Molecular signatures of G-protein-coupled receptors. *Nature* **494**, 185–194 <https://doi.org/10.1038/nature11896>
- 41 Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A. et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. *Science* **289**, 739–745 <https://doi.org/10.1126/science.289.5480.739>
- 42 Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S. et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature* **477**, 549–555 <https://doi.org/10.1038/nature10361>
- 43 Stropes, M.P. and Miller, W.E. (2008) Functional analysis of human cytomegalovirus pUS28 mutants in infected cells. *J. Gen. Virol.* **89**(Pt 1), 97–105 <https://doi.org/10.1099/vir.0.83226-0>
- 44 Krishna, B.A., Poole, E.L., Jackson, S.E., Smit, M.J., Wills, M.R. and Sinclair, J.H. (2017) Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection. *mBio* **8**, e01754–17 <https://doi.org/10.1128/mBio.01754-17>
- 45 Costa, H., Touma, J., Davoudi, B., Benard, M., Sauer, T., Geisler, J. et al. (2019) Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer. *J. Cancer Res. Clin. Oncol.* **145**, 2083–2095 <https://doi.org/10.1007/s00432-019-02946-8>
- 46 Harkins, L., Volk, A.L., Samanta, M., Mikolaenko, I., Britt, W.J., Bland, K.I. et al. (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. *Lancet* **360**, 1557–1563 [https://doi.org/10.1016/S0140-6736\(02\)11524-8](https://doi.org/10.1016/S0140-6736(02)11524-8)
- 47 Teo, W.H., Chen, H.P., Huang, J.C. and Chan, Y.J. (2017) Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. *Int. J. Oncol.* **51**, 1415–1426 <https://doi.org/10.3892/ijo.2017.4135>
- 48 Cai, Z.Z., Xu, J.G., Zhou, Y.H., Zheng, J.H., Lin, K.Z., Zheng, S.Z. et al. (2016) Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer. *World J. Gastroenterol.* **22**, 2789–2798 <https://doi.org/10.3748/wjg.v22.i9.2789>
- 49 Samanta, M., Harkins, L., Klemm, K., Britt, W.J. and Cobbs, C.S. (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. *J. Urol.* **170**, 998–1002 <https://doi.org/10.1097/01.ju.0000080263.46164.97>
- 50 Huang, G., Yan, Q., Wang, Z., Chen, X., Zhang, X., Guo, Y. et al. (2002) Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease. *Int. J. Oncol.* **21**, 31–36 PMID: 12063546
- 51 Price, R.L., Harkins, L., Chiocca, E.A., Zhang, P.J., Kurt, H. and Iwenofu, O.H. (2017) Human cytomegalovirus is present in alveolar soft part sarcoma. *Appl. Immunohistochem. Mol. Morphol.* **25**, 615–619 <https://doi.org/10.1097/PAI.0000000000000354>
- 52 Farias, K. and Moreli, M.L. (2019) Floriano VG, da Costa VG. Evidence based on a meta-analysis of human cytomegalovirus infection in glioma. *Arch. Virol.* **164**, 1249–1257 <https://doi.org/10.1007/s00705-019-04206-z>
- 53 Cobbs, C.S., Harkins, L., Samanta, M., Gillespie, G.Y., Bharara, S., King, P.H. et al. (2002) Human cytomegalovirus infection and expression in human malignant glioma. *Cancer Res.* **62**, 3347–3350 PMID: 12067971
- 54 Mitchell, D.A., Xie, W., Schmittling, R., Learn, C., Friedman, A., McLendon, R.E. et al. (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. *Neuro Oncol.* **10**, 10–18 <https://doi.org/10.1215/15228517-2007-035>
- 55 Baryawno, N., Rahbar, A., Wolmer-Solberg, N., Taher, C., Odeberg, J., Darabi, A. et al. (2011) Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. *J. Clin. Invest.* **121**, 4043–4055 <https://doi.org/10.1172/JCI57147>
- 56 Soroceanu, L., Matlaf, L., Bezrookove, V., Harkins, L., Martinez, R., Greene, M. et al. (2011) Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. *Cancer Res.* **71**, 6643–6653 <https://doi.org/10.1158/0008-5472.CAN-11-0744>
- 57 Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernandez de la Cruz, O.N. and Lopez-Gonzalez, J.S. (2019) Contribution of Angiogenesis to Inflammation and Cancer. *Front. Oncol.* **9**, 1399 <https://doi.org/10.3389/fonc.2019.01399>
- 58 Spector, D.H. (2015) Human cytomegalovirus riding the cell cycle. *Med. Microbiol. Immunol.* **204**, 409–419 <https://doi.org/10.1007/s00430-015-0396-z>
- 59 Salvant, B.S., Fortunato, E.A. and Spector, D.H. (1998) Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. *J. Virol.* **72**, 3729–3741 <https://doi.org/10.1128/JVI.72.5.3729-3741.1998>
- 60 Fortunato, E.A., Sanchez, V., Yen, J.Y. and Spector, D.H. (2002) Infection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome. *J. Virol.* **76**, 5369–5379 <https://doi.org/10.1128/JVI.76.11.5369-5379.2002>
- 61 Feitelson, M.A., Arzumanyan, A., Kulathinal, R.J., Blain, S.W., Holcombe, R.F., Mahajna, J. et al. (2015) Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. *Semin. Cancer Biol.* **35**, S25–S54 <https://doi.org/10.1016/j.semcancer.2015.02.006>
- 62 Lee, H., Jeong, A.J. and Ye, S.K. (2019) Highlighted STAT3 as a potential drug target for cancer therapy. *BMB Rep.* **52**, 415–423 <https://doi.org/10.5483/BMBRep.2019.52.7.152>
- 63 Yu, H., Lee, H., Herrmann, A., Buettner, R. and Jove, R. (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. *Nat. Rev. Cancer* **14**, 736–746 <https://doi.org/10.1038/nrc3818>

- 64 Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H. et al. (2017) Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. *Cancer Sci.* **108**, 1947–1952 <https://doi.org/10.1111/cas.13332>
- 65 Halwachs-Baumann, G., Weihrauch, G., Gruber, H.J., Desoye, G. and Sinzger, C. (2006) hCMV induced IL-6 release in trophoblast and trophoblast like cells. *J. Clin. Virol.* **37**, 91–97 <https://doi.org/10.1016/j.jcv.2006.06.006>
- 66 Wang, H., Lathia, J.D., Wu, Q., Wang, J., Li, Z., Heddeston, J.M. et al. (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. *Stem Cells* **27**, 2393–2404 <https://doi.org/10.1002/stem.188>
- 67 Soroceanu, L. and Cobbs, C.S. (2011) Is HCMV a tumor promoter? *Virus Res.* **157**, 193–203 <https://doi.org/10.1016/j.virusres.2010.10.026>
- 68 Mori, T., Miyamoto, T., Yoshida, H., Asakawa, M., Kawasumi, M., Kobayashi, T. et al. (2011) IL-1 β and TNF α -initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. *Int. Immunol.* **23**, 701–712 <https://doi.org/10.1093/intimm/dxr077>
- 69 Han, D., Yu, T., Dong, N., Wang, B., Sun, F. and Jiang, D. (2019) Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. *J. Exp. Clin. Cancer Res.* **38**, 289 <https://doi.org/10.1186/s13046-019-1289-6>
- 70 Krishnamurthy, N. and Kurzrock, R. (2018) Targeting the Wnt/ β -catenin pathway in cancer: update on effectors and inhibitors. *Cancer Treat Rev.* **62**, 50–60 <https://doi.org/10.1016/j.ctrv.2017.11.002>
- 71 Bongers, G., Maussang, D., Muniz, L.R., Noriega, V.M., Fraile-Ramos, A., Barker, N. et al. (2010) The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. *J. Clin. Invest.* **120**, 3969–3978 <https://doi.org/10.1172/JCI42563>
- 72 Reeves, M.B. and Compton, T. (2011) Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. *J. Virol.* **85**, 12750–8 <https://doi.org/10.1128/JVI.05878-11>
- 73 Hargett, D. and Shenk, T.E. (2010) Experimental human cytomegalovirus latency in CD14 $^{+}$ monocytes. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 20039–20044 <https://doi.org/10.1073/pnas.1014509107>
- 74 Steinhoff, G., You, X.M., Steinmuller, C., Boeke, K., Stals, F.S., Bruggeman, C.A. et al. (1995) Induction of endothelial adhesion molecules by rat cytomegalovirus in allogeneic lung transplantation in the rat. *Scand. J. Infect. Dis. Suppl.* **99**, 58–60 PMID: 8668943
- 75 Chan, G., Nogalski, M.T. and Yurochko, A.D. (2009) Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 22369–22374 <https://doi.org/10.1073/pnas.0908787106>
- 76 Zuazo-Gaztelu, I. and Casanovas, O. (2018) Unraveling the role of angiogenesis in cancer ecosystems. *Front. Oncol.* **8**, 248 <https://doi.org/10.3389/fonc.2018.00248>
- 77 Zimna, A. and Kurpisz, M. (2015) Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. *Biomed. Res. Int.* **2015**, 549412 <https://doi.org/10.1155/2015/549412>
- 78 McFarlane, S., Nicholl, M.J., Sutherland, J.S. and Preston, C.M. (2011) Interaction of the human cytomegalovirus particle with the host cell induces hypoxia-inducible factor 1 α . *Virology* **414**, 83–90 <https://doi.org/10.1016/j.virol.2011.03.005>
- 79 Apte, R.S., Chen, D.S. and Ferrara, N. (2019) VEGF in signaling and disease: beyond discovery and development. *Cell* **176**, 1248–1264 <https://doi.org/10.1016/j.cell.2019.01.021>
- 80 Sun, X. and Li, Q. (2018) Prostaglandin EP2 receptor: novel therapeutic target for human cancers (review). *Int. J. Mol. Med.* **42**, 1203–1214 <https://doi.org/10.3892/ijmm.2018.3744>
- 81 Zauberman, A., Zipori, D., Krupsky, M. and Ben-Levy, R. (1999) Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. *Oncogene* **18**, 3886–3893 <https://doi.org/10.1038/sj.onc.1202738>
- 82 Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G. and Schaper, F. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem. J.* **374**(Pt 1), 1–20 <https://doi.org/10.1042/bj20030407>
- 83 Steven, A. and Seliger, B. (2016) Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. *Oncotarget* **7**, 35454–35465 <https://doi.org/10.18632/oncotarget.7721>
- 84 Wen, D.Q., Zhang, Y.Y., Lv, L.P., Zhou, X.P., Yan, F., Ma, P. et al. (2009) Human cytomegalovirus-encoded chemokine receptor homolog US28 stimulates the major immediate early gene promoter/enhancer via the induction of CREB. *J. Recept. Signal. Transduct. Res.* **29**, 266–273 <https://doi.org/10.1080/10799890903178141>
- 85 Collins-McMillen, D., Buehler, J., Peppenelli, M. and Goodrum, F. (2018) Molecular determinants and the regulation of human cytomegalovirus latency and reactivation. *Viruses* **10**, 444 <https://doi.org/10.3390/v10080444>
- 86 Graef, I.A., Chen, F., Chen, L., Kuo, A. and Crabtree, G.R. (2001) Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. *Cell* **105**, 863–875 [https://doi.org/10.1016/S0092-8674\(01\)00396-8](https://doi.org/10.1016/S0092-8674(01)00396-8)
- 87 Duque, J., Fresno, M. and Iniguez, M.A. (2005) Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. *J. Biol. Chem.* **280**, 8686–8693 <https://doi.org/10.1074/jbc.M413076200>
- 88 Flockhart, R.J., Diffey, B.L., Farr, P.M., Lloyd, J. and Reynolds, N.J. (2008) NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. *FASEB J.* **22**, 4218–4227 <https://doi.org/10.1096/fj.08-113076>
- 89 Iniguez, M.A., Martinez-Martinez, S., Punzon, C., Redondo, J.M. and Fresno, M. (2000) An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. *J. Biol. Chem.* **275**, 23627–23635 <https://doi.org/10.1074/jbc.M001381200>
- 90 Blanco, A., Alvarez, S., Fresno, M. and Munoz-Fernandez, M.A. (2008) Extracellular HIV-Tat induces cyclooxygenase-2 in glial cells through activation of nuclear factor of activated T cells. *J. Immunol.* **180**, 530–540 <https://doi.org/10.4049/jimmunol.180.1.530>
- 91 Corral, R.S., Iniguez, M.A., Duque, J., Lopez-Perez, R. and Fresno, M. (2007) Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. *Oncogene* **26**, 958–969 <https://doi.org/10.1038/sj.onc.1209856>
- 92 Shou, J., Jing, J., Xie, J., You, L., Jing, Z., Yao, J. et al. (2015) Nuclear factor of activated T cells in cancer development and treatment. *Cancer Lett.* **361**, 174–184 <https://doi.org/10.1016/j.canlet.2015.03.005>
- 93 Zhang, J., He, S., Wang, Y., Brulois, K., Lan, K., Jung, J.U. et al. (2015) Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. *PLoS Pathog.* **11**, e1004768 <https://doi.org/10.1371/journal.ppat.1004768>

- 94 Hogan, P.G., Chen, L., Nardone, J. and Rao, A. (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes Dev.* **17**, 2205–2232 <https://doi.org/10.1101/gad.1102703>
- 95 Landini, M.P. (1984) Early enhanced glucose uptake in human cytomegalovirus-infected cells. *J. Gen. Virol.* **65**(Pt 7), 1229–1232 <https://doi.org/10.1099/0022-1317-65-7-1229>
- 96 Vastag, L., Koyuncu, E., Grady, S.L., Shenk, T.E. and Rabinowitz, J.D. (2011) Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism. *PLoS Pathog.* **7**, e1002124 <https://doi.org/10.1371/journal.ppat.1002124>
- 97 Yu, Y., Maguire, T.G. and Alwine, J.C. (2011) Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection. *J. Virol.* **85**, 1573–1580 <https://doi.org/10.1128/JVI.01967-10>
- 98 Hsu, M.C. and Hung, W.C. (2018) Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling. *Mol. Cancer* **17**, 35 <https://doi.org/10.1186/s12943-018-0791-3>
- 99 Wong, N., Ojo, D., Yan, J. and Tang, D. (2015) PKM2 contributes to cancer metabolism. *Cancer Lett.* **356**(2 Pt A), 184–191 <https://doi.org/10.1016/j.canlet.2014.01.031>
- 100 Hitosugi, T., Kang, S., Vander Heiden, M.G., Chung, T.W., Elf, S., Lythgoe, K. et al. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the warburg effect and tumor growth. *Sci. Signal.* **2**, ra73 <https://doi.org/10.1126/scisignal.2000431>
- 101 Gao, X., Wang, H., Yang, J.J., Liu, X. and Liu, Z.R. (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. *Mol. Cell* **45**, 598–609 <https://doi.org/10.1016/j.molcel.2012.01.001>
- 102 Gao, X., Wang, H., Yang, J.J., Chen, J., Jie, J., Li, L. et al. (2013) Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. *J. Biol. Chem.* **288**, 15971–9 <https://doi.org/10.1074/jbc.M112.448753>
- 103 Zhou, Z., Li, M., Zhang, L., Zhao, H., Sahin, O., Chen, J. et al. (2018) Oncogenic Kinase-induced PKM2 tyrosine 105 phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells. *Cancer Res.* **78**, 2248–2261 <https://doi.org/10.1158/0008-5472.CAN-17-2726>
- 104 Filipp, F.V. (2013) Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. *J. Carcinog.* **12**, 14 <https://doi.org/10.4103/1477-3163.115423>
- 105 Demaria, M. and Poli, V. (2012) PKM2, STAT3 and HIF-1alpha: The Warburg's vicious circle. *JAKSTAT* **1**, 194–196 <https://doi.org/10.4161/jkst.20662>
- 106 Ancy, P.B., Contat, C. and Meylan, E. (2018) Glucose transporters in cancer - from tumor cells to the tumor microenvironment. *FEBS J.* **285**, 2926–2943 <https://doi.org/10.1111/febs.14577>
- 107 Ganapathy-Kanniappan, S. (2018) Evolution of GAPDH as a druggable target of tumor glycolysis? *Expert. Opin. Ther. Targets* **22**, 295–298 <https://doi.org/10.1080/14728222.2018.1449834>
- 108 Shestov, A.A., Liu, X., Ser, Z., Cluntun, A.A., Hung, Y.P., Huang, L. et al. (2014) Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. *eLife* **3**, e03342 <https://doi.org/10.7554/eLife.03342>